About this trial
Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients will recover quickly, some will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS consortium aims to identify clinical, genetic, and other molecular markers and combinations there of predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome. PROGRESS-COMORB aims to extend findings from the previous PROGRESS study to patients with more severe preexisting conditions and immunosuppression.
Eligibility criteria
Qualifiers
Hospitalization with community acquired pneumonia (CAP) confirmed by pulmonary infiltrate in chest imaging
Valid informed consent form
Working diagnosis of CAP by enrolling physician
No hospitalization for any reason within 28 days prior to hospitalization for the current episode of CAP
Disqualifiers
Participation in this study at an earlier time
More than 48 hours in the hospital before enrollment (for patients directly to intensive care: more than 7 days)
Pregnancy
Breastfeeding
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps
Lead sponsor
Charite University, Berlin, Germany
Collaborator
University of Leipzig
Collaborator
Jena University Hospital
Collaborator